Cargando…

Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption

Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Rachael, Wiley, Claire A., Droste, Emma L., Robertson, James, Inman, Brant A., Breen, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153751/
https://www.ncbi.nlm.nih.gov/pubmed/37079639
http://dx.doi.org/10.1371/journal.pgen.1010575
_version_ 1785035985014226944
author Thomas, Rachael
Wiley, Claire A.
Droste, Emma L.
Robertson, James
Inman, Brant A.
Breen, Matthew
author_facet Thomas, Rachael
Wiley, Claire A.
Droste, Emma L.
Robertson, James
Inman, Brant A.
Breen, Matthew
author_sort Thomas, Rachael
collection PubMed
description Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeutic target; however, due to their relative infrequency, the remaining 15% of cases remain understudied at the molecular level. We performed whole exome sequencing analysis of 28 canine urine sediments exhibiting the characteristic DNA copy number signatures of canine UC, in which the BRAF V595E mutation was undetected (UD(V595E) specimens). Among these we identified 13 specimens (46%) harboring short in-frame deletions within either BRAF exon 12 (7/28 cases) or MAP2K1 exons 2 or 3 (6/28 cases). Orthologous variants occur in several human cancer subtypes and confer structural changes to the protein product that are predictive of response to different classes of small molecule MAPK pathway inhibitors. DNA damage response and repair genes, and chromatin modifiers were also recurrently mutated in UD(V595E) specimens, as were genes that are positive predictors of immunotherapy response in human cancers. Our findings suggest that short in-frame deletions within BRAF exon 12 and MAP2K1 exons 2 and 3 in UD(V595E) cases are alternative MAPK-pathway activating events that may have significant therapeutic implications for selecting first-line treatment for canine UC. We developed a simple, cost-effective capillary electrophoresis genotyping assay for detection of these deletions in parallel with the BRAF V595E mutation. The identification of these deletion events in dogs offers a compelling cross-species platform in which to study the relationship between somatic alteration, protein conformation, and therapeutic sensitivity.
format Online
Article
Text
id pubmed-10153751
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-101537512023-05-03 Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption Thomas, Rachael Wiley, Claire A. Droste, Emma L. Robertson, James Inman, Brant A. Breen, Matthew PLoS Genet Research Article Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeutic target; however, due to their relative infrequency, the remaining 15% of cases remain understudied at the molecular level. We performed whole exome sequencing analysis of 28 canine urine sediments exhibiting the characteristic DNA copy number signatures of canine UC, in which the BRAF V595E mutation was undetected (UD(V595E) specimens). Among these we identified 13 specimens (46%) harboring short in-frame deletions within either BRAF exon 12 (7/28 cases) or MAP2K1 exons 2 or 3 (6/28 cases). Orthologous variants occur in several human cancer subtypes and confer structural changes to the protein product that are predictive of response to different classes of small molecule MAPK pathway inhibitors. DNA damage response and repair genes, and chromatin modifiers were also recurrently mutated in UD(V595E) specimens, as were genes that are positive predictors of immunotherapy response in human cancers. Our findings suggest that short in-frame deletions within BRAF exon 12 and MAP2K1 exons 2 and 3 in UD(V595E) cases are alternative MAPK-pathway activating events that may have significant therapeutic implications for selecting first-line treatment for canine UC. We developed a simple, cost-effective capillary electrophoresis genotyping assay for detection of these deletions in parallel with the BRAF V595E mutation. The identification of these deletion events in dogs offers a compelling cross-species platform in which to study the relationship between somatic alteration, protein conformation, and therapeutic sensitivity. Public Library of Science 2023-04-20 /pmc/articles/PMC10153751/ /pubmed/37079639 http://dx.doi.org/10.1371/journal.pgen.1010575 Text en © 2023 Thomas et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Thomas, Rachael
Wiley, Claire A.
Droste, Emma L.
Robertson, James
Inman, Brant A.
Breen, Matthew
Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption
title Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption
title_full Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption
title_fullStr Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption
title_full_unstemmed Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption
title_short Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption
title_sort whole exome sequencing analysis of canine urothelial carcinomas without braf v595e mutation: short in-frame deletions in braf and map2k1 suggest alternative mechanisms for mapk pathway disruption
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153751/
https://www.ncbi.nlm.nih.gov/pubmed/37079639
http://dx.doi.org/10.1371/journal.pgen.1010575
work_keys_str_mv AT thomasrachael wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT wileyclairea wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT drosteemmal wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT robertsonjames wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT inmanbranta wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT breenmatthew wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption